{"id":314308,"date":"2020-01-24T18:35:29","date_gmt":"2020-01-25T02:35:29","guid":{"rendered":"https:\/\/nai500.com\/blog\/2020\/01\/beigenes-tislelizumab-could-challenge-mercks-keytruda\/"},"modified":"2020-01-24T18:36:11","modified_gmt":"2020-01-25T02:36:11","slug":"%e9%bb%98%e5%85%8b%e7%9a%84-keytruda-%e8%bf%8e%e6%8c%91%e6%88%b0%e7%99%be%e6%bf%9f%e7%a5%9e%e5%b7%9e-tislelizumab-%e8%88%87%e4%b9%8b%e7%88%ad%e9%8b%92","status":"publish","type":"post","link":"https:\/\/nai500.com\/zh-hant\/blog\/2020\/01\/%e9%bb%98%e5%85%8b%e7%9a%84-keytruda-%e8%bf%8e%e6%8c%91%e6%88%b0%e7%99%be%e6%bf%9f%e7%a5%9e%e5%b7%9e-tislelizumab-%e8%88%87%e4%b9%8b%e7%88%ad%e9%8b%92\/","title":{"rendered":"\u9ed8\u514b\u7684Keytruda\u8fce\u6311\u6230\uff0c\u767e\u6fdf\u795e\u5ddeTislelizumab\u8207\u4e4b\u722d\u92d2"},"content":{"rendered":"<p>\u5728\u4e2d\u570b\u5317\u4eac\u548c\u99ac\u85a9\u8af8\u585e\u5dde\u528d\u6a4b\u8a2d\u6709\u8fa6\u4e8b\u8655\u7684\u767e\u6fdf\u795e\u5dde\u672c\u5468\u65e9\u4e9b\u6642\u5019\u5ba3\u4f48\u4e86\u5176\u6297PD-1\u6297\u9ad4\u66ff\u96f7\u5229\u73e0\u55ae\u6297\uff08Tislelizumab\uff09\u806f\u5408\u5169\u7a2e\u5316\u7642\u85e5\u7269\u6cbb\u7642\u9c57\u72c0\u975e\u5c0f\u7d30\u80de\u80ba\u764c\uff08NSCLC\uff09\u7684\u91cd\u8981III\u671f\u8a66\u9a57\u7d50\u679c\u3002Tislelizumab\u662f\u4e00\u7a2e\u6aa2\u67e5\u9ede\u6291\u5236\u5291\uff0c\u5728\u8a08\u5283\u7684\u4e2d\u671f\u5206\u6790\u4e2d\u9054\u5230\u4e86\u6539\u5584\u7121\u9032\u5c55\u751f\u5b58\u671f\uff08PFS\uff09\u7684\u4e3b\u8981\u7d42\u9ede\u3002\u5982Tislelizumab\u7372\u6279\uff0c\u5b83\u5c07\u8207\u6aa2\u67e5\u9ede\u6291\u5236\u5291\u5e02\u5834\u7684\u4e3b\u8981\u53c3\u8207\u8005\u9ed8\u514b\u53ca\u5176Keytruda\uff08pembrolizumab\uff09\u7af6\u722d\u3002<\/p>\n<p>\u767e\u6fdf\u795e\u5dde\u8868\u793a\u8a08\u5283\u5728\u4e2d\u570b\u5c0b\u6c42\u6279\u51c6Tislelizumab\u3002Tislelizumab\u6b64\u524d\u5df2\u7d93\u88ab\u6279\u51c6\u7528\u65bc\u6cbb\u7642\u5148\u524d\u5df2\u63a5\u53d7\u904e\u5169\u6b21\u764c\u75c7\u6cbb\u7642\u7684\u970d\u5947\u91d1\u6dcb\u5df4\u7624\u60a3\u8005\u3002\u53bb\u5e74\uff0c\u9ed8\u514b\uff08Merck\uff09\u7684Keytruda\u88ab\u6279\u51c6\u7528\u65bc\u4e2d\u570b\u7684NSCLC\u3002<\/p>\n<p>\u9ed8\u514b\u7684Keytruda\u6709\u671b\u53d6\u4ee3\u4e16\u754c\u4e0a\u6700\u66a2\u92b7\u7684\u85e5\u7269\u3002\u8a72\u982d\u929c\u76ee\u524d\u5c6c\uffff\u827e\u4f2f\u7dad\u7684Humira\uff0c\u8a72\u516c\u53f8\u6b63\u9762\u81e8\u65e5\u76ca\u6fc0\u70c8\u7684\u7af6\u722d\u548c\u5c08\u5229\u5230\u671f\u3002\u4f3c\u4e4eKeytruda\u5927\u7d04\u6bcf\u500b\u661f\u671f\u90fd\u88ab\u6279\u51c6\u7528\u65bc\u65b0\u7684\u9069\u61c9\u75c7\u3002\u5118\u7ba1\u5e02\u5834\u4e0a\u78ba\u5be6\u5b58\u5728\u5176\u4ed6\u6aa2\u67e5\u9ede\u6291\u5236\u5291\uff0c\u4f46\u6c92\u6709\u54ea\u4e00\u7a2e\u7279\u5225\u63a5\u8fd1Keytruda\u7684\u7d71\u6cbb\u5730\u4f4d\u3002<\/p>\n<p>\u5728\u767e\u6fdf\u795e\u5dde\u8a66\u9a57\u4e2d\uff0c\u5148\u524d\u672a\u63a5\u53d7\u6cbb\u7642\u7684\u665a\u671f\u9c57\u72c0NSCLC\u60a3\u8005\u63a5\u53d7\u4e86Tislelizumab\u806f\u5408\u7d2b\u6749\u9187\u548c\u5361\u9251\u806f\u5408\u6cbb\u7642\u3002\u6839\u64da\u9810\u5148\u8a08\u5283\u7684\u4e2d\u671f\u5206\u6790\uff0c\u8207\u55ae\u7368\u5316\u7642\u76f8\u6bd4\uff0c\u8a72\u8a66\u9a57\u7684\u5169\u500bTislelizumab\u6cbb\u7642\u7d44\u5747\u901a\u904e\u4e86\u7642\u6548\u908a\u754c\u3002<\/p>\n<p>\u767e\u6fdf\u795e\u5dde\u514d\u75ab\u816b\u7624\u5b78\u91ab\u5b78\u5b98 Yong Ben\u8aaa\uff1a\u201cTislelizumab\u6700\u8fd1\u5728\u4e2d\u570b\u88ab\u6279\u51c6\u7528\u65bc\u5fa9\u767c\u6027\u6216\u96e3\u6cbb\u6027\u7d93\u5178\u970d\u5947\u91d1\u6dcb\u5df4\u7624\u60a3\u8005\uff0c\u6211\u5011\u64c1\u6709\u5ee3\u6cdb\u7684\u958b\u767c\u8a08\u5283\uff0c\u67095,000\u4f8b\u60a3\u8005\u53c3\u52a0\u4e86\u8d85\u904e25\u4f8btislelizumab\u7814\u7a76\uff0c\u5305\u62ec15\u9805\u53ef\u80fd\u555f\u7528\u8a3b\u518a\u7684\u8a66\u9a57\u3002\u6211\u5011\u5c0dTislelizumab\u5728\u8a72III\u671f\u81e8\u5e8a\u8a66\u9a57\u4e2d\u986f\u793a\u7684\u4ee4\u4eba\u4fe1\u670d\u7684\u7d50\u679c\u4ee5\u53ca\u5176\u5728\u4e2d\u570b\u665a\u671f\u9c57\u72c0NSCLC\u60a3\u8005\u4e2d\u4f5c\u70ba\u4e00\u7dda\u6cbb\u7642\u7684\u6f5b\u5728\u7528\u9014\u611f\u5230\u975e\u5e38\u8208\u596e\u3002\u6211\u5011\u671f\u5f85\u7e7c\u7e8c\u9032\u884cTislelizumab\u6cbb\u7642\u80ba\u764c\u4e2d\u7684\u958b\u767c\u8a08\u5283\uff0c\u5176\u4e2d\u5305\u62ec\u5176\u4ed6\u4e09\u9805III\u671f\u8a66\u9a57\uff0c\u4e26\u5831\u544a\u66f4\u591a\u6578\u64da\u3002\u201d<\/p>\n<p>\u8207\u5927\u591a\u6578\u897f\u65b9\u570b\u5bb6\u4e0d\u540c\uff0c\u4e2d\u570b\u7684\u80ba\u764c\u767c\u75c5\u7387\u6b63\u5728\u4e0a\u5347\u3002 2018\u5e74\uff0c\u4e2d\u570b\u7d04\u6709770,000\u4f8b\u80ba\u764c\u65b0\u75c5\u4f8b\uff0c2018\u5e74\u5168\u570b\u7d04\u6709690,500\u4f8b\u6b7b\u4ea1\u3002NSCLC\u662f\u4e2d\u570b\u6700\u5e38\u898b\u7684\u80ba\u764c\u5f62\u5f0f\u3002<\/p>\n<p>Tislelizumab\u6700\u521d\u65bc2017\u5e74\u88abCelgene\u6536\u8cfc\uff0c\u4f46Celgene\u5c07\u6b0a\u5229\u6b78\u9084\u4e86\u767e\u6fdf\u795e\u5dde\u3002\u5118\u7ba1\u9ed8\u514b\u7684Keytruda\u5728\u5e02\u5834\u4e0a\u5360\u4e3b\u5c0e\u5730\u4f4d\uff0c\u4f46\u5206\u6790\u5e2b\u5c0d\u9019\u7a2e\u85e5\u7269\u7684\u904e\u5ea6\u4f9d\u8cf4\u8868\u793a\u4e86\u64d4\u6182\u3002\u6709\u5831\u544a\u6307\u51fa\uff0cKeytruda\u4e26\u6c92\u6709\u5ef6\u9577\u5c0f\u7d30\u80de\u80ba\u764c\uff08SCLC\uff09\u60a3\u8005\u7684\u58fd\u547d\uff0c\u4f46\u5b83\u8207\u5316\u7642\u806f\u5408\u4f7f\u7528\u78ba\u5be6\u53ef\u4ee5\u6e1b\u7de9\u764c\u75c7\u7684\u9032\u5c55\u3002<\/p>\n<p>\u767e\u6fdf\u795e\u5dde\u7684Tislelizumab\u53ef\u80fd\u6703\u6210\u70ba\u4e2d\u570b\u5e02\u5834\u4e0a\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u7684\u66f4\u76f4\u63a5\u7af6\u722d\u5c0d\u624b\uff0c\u5118\u7ba1\u9ed8\u514b\u53ef\u80fd\u6703\u5728\u5169\u5e74\u5de6\u53f3\u7684\u6642\u9593\u88e1\u611f\u89ba\u4e0d\u5230\u9019\u7a2e\u7af6\u722d\u3002\u52302025\u5e74\uff0cKeytruda\u7684\u5e74\u92b7\u552e\u984d\u9810\u8a08\u5c07\u9054\u5230225\u5104\u7f8e\u5143\u7684\u5cf0\u503c\u3002<\/p>\n<p>\u82f1\u6587\u4f86\u6e90\uff1aBiospace<\/p>\n","protected":false},"excerpt":{"rendered":"<p>BeiGene, with offices in Beijing, China and Cambridge, Massachusetts, announced results from its pivotal Phase III trial of its anti-PD-1 antibody tislelizumab in combination with two chemotherapy agents in squamous non-small cell lung cancer (NSCLC).<\/p>\n","protected":false},"author":9,"featured_media":314293,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[426],"tags":[809,927,563,644],"class_list":["post-314308","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-news-zh-hant","tag-809","tag-927","tag--zh-hant","tag-644","sectors-life-science-zh-hant","locations-china-zh-hant","locations-us-zh-hant"],"acf":[],"_links":{"self":[{"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/posts\/314308","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/comments?post=314308"}],"version-history":[{"count":0,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/posts\/314308\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/media\/314293"}],"wp:attachment":[{"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/media?parent=314308"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/categories?post=314308"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/tags?post=314308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}